Sarepta Therapeutics, Inc. (SRPT)
Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 25.3205
- Book/Share 13.8502
- PB 1.6491
- Debt/Equity 0.9974
- CurrentRatio 2.8882
- ROIC -0.0008
- MktCap 2231673560.0
- FreeCF/Share -4.5053
- PFCF -5.0542
- PE -38.623
- Debt/Assets 0.3679
- DivYield 0
- ROE -0.0442
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SRPT | BMO Capital Markets | Market Perform | Outperform | -- | $50 | Sept. 22, 2025 |
| Upgrade | SRPT | Barclays | Underweight | Equal Weight | -- | $22 | July 29, 2025 |
| Initiation | SRPT | Bernstein | -- | Market Perform | -- | $13 | July 29, 2025 |
| Upgrade | SRPT | Oppenheimer | Perform | Outperform | -- | $37 | July 29, 2025 |
| Reiterated | SRPT | H.C. Wainwright | -- | Sell | -- | $5 | July 29, 2025 |
| Upgrade | SRPT | JP Morgan | Underweight | Neutral | -- | $24 | July 29, 2025 |
| Downgrade | SRPT | Barclays | Equal Weight | Underweight | -- | $10 | July 28, 2025 |
| Downgrade | SRPT | JP Morgan | Neutral | Underweight | -- | -- | July 25, 2025 |
| Initiation | SRPT | Citigroup | -- | Sell | -- | $7 | July 24, 2025 |
| Downgrade | SRPT | BofA Securities | Neutral | Underperform | -- | $10 | July 23, 2025 |
News
Sarepta Therapeutics' stock falls after patient dies of liver failure
Published: March 18, 2025 by: Market Watch
Sentiment: Negative
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. “In the past decade, there have been significant advancements in the tr.
Read More
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz …
Read More
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Douglas S. Ingram
- Employees 1372